Campbell & CO Investment Adviser LLC Buys Shares of 142,198 Sanofi $SNY

Campbell & CO Investment Adviser LLC bought a new stake in Sanofi (NASDAQ:SNY) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 142,198 shares of the company’s stock, valued at approximately $7,886,000. Sanofi accounts for about 0.6% of Campbell & CO Investment Adviser LLC’s portfolio, making the stock its 5th largest position.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SNY. Nuveen LLC acquired a new position in Sanofi in the first quarter valued at about $177,831,000. Federated Hermes Inc. grew its stake in Sanofi by 58.5% in the first quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock valued at $218,933,000 after acquiring an additional 1,456,269 shares during the period. Point72 Asset Management L.P. grew its stake in Sanofi by 969.6% in the fourth quarter. Point72 Asset Management L.P. now owns 950,649 shares of the company’s stock valued at $45,850,000 after acquiring an additional 861,770 shares during the period. Regal Partners Ltd acquired a new position in Sanofi in the fourth quarter valued at about $35,034,000. Finally, Vestal Point Capital LP grew its stake in Sanofi by 400.0% in the fourth quarter. Vestal Point Capital LP now owns 750,000 shares of the company’s stock valued at $36,172,000 after acquiring an additional 600,000 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on SNY shares. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Sanofi in a research note on Tuesday, August 5th. Morgan Stanley set a $56.00 price target on Sanofi in a report on Monday, June 2nd. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Guggenheim restated a “buy” rating on shares of Sanofi in a report on Tuesday, June 3rd. Finally, Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Three investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $62.00.

Sanofi Stock Performance

SNY opened at $51.35 on Friday. Sanofi has a 52-week low of $44.73 and a 52-week high of $60.12. The firm has a market capitalization of $126.09 billion, a PE ratio of 12.34, a PEG ratio of 1.22 and a beta of 0.48. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The business’s 50-day simple moving average is $48.62 and its 200 day simple moving average is $51.71.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The company had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. During the same quarter in the previous year, the company posted $1.73 EPS. The business’s revenue was down 7.0% on a year-over-year basis. As a group, sell-side analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.